4 - Heartflow, Inc. (0001464521) (Issuer)

3 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

4 - Heartflow, Inc. (0001464521) (Issuer)

10-Q - Heartflow, Inc. (0001464521) (Filer)

8-K - Heartflow, Inc. (0001464521) (Filer)

8-K - Heartflow, Inc. (0001464521) (Filer)

S-8 - Heartflow, Inc. (0001464521) (Filer)

S-8 - Heartflow, Inc. (0001464521) (Filer)

8-K - Heartflow, Inc. (0001464521) (Filer)

-- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth. -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care. Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than

MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna across all of its lines of bu

MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET. A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow, Inc.Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosab

MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2